Samuel L Aitken

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6539325/publications.pdf

Version: 2024-02-01

92 papers	2,747 citations	236833 25 h-index	206029 48 g-index
94 all docs	94 docs citations	94 times ranked	2905 citing authors

#	Article	IF	Citations
1	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2021, 72, e169-e183.	2.9	292
2	Infectious Diseases Society of America Guidance on the Treatment of AmpC Î²-Lactamaseâ€“Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clinical Infectious Diseases, 2022, 74, 2089-2114.	2.9	262
3	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), andPseudomonas aeruginosawith Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2021, 72, 1109-1116.	2.9	251
4	Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2022, 75, 187-212.	2.9	182
5	Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 2017, 65, 158-161.	2.9	123
6	Antifungal Resistance: a Concerning Trend for the Present and Future. Current Infectious Disease Reports, 2019, 21, 47.	1.3	80
7	Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2019, 68, 1641-1649.	2.9	71
8	Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	66
9	Successful Treatment of Bloodstream Infection Due to Metallo-Î²-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient. Antimicrobial Agents and Chemotherapy, 2016, 60, 5130-5134.	1.4	61
10	Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. Journal of Hospital Infection, 2016, 93, 286-289.	1.4	59
11	Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. International Journal of Antimicrobial Agents, 2015, 45, 541-544.	1.1	58
12	Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum Î²-Lactams for Major Gram-Negative Bacterial Pathogens. Clinical Infectious Diseases, 2017, 65, 738-745.	2.9	56
13	High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-Î²-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.. Clinical Infectious Diseases, 2016, 63, 954-958.	2.9	55
14	Aerosolized ribavirin: the most expensive drug for pneumonia. Transplant Infectious Disease, 2016, 18, 634-636.	0.7	52
15	Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 303-313.	0.5	45
16	American Society for Transplantation and Cellular Therapy Series: #3â€”Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 707-719.	0.6	45
17	Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clinical Infectious Diseases, 2021, 73, 1346-1354.	2.9	43
18	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clinical Infectious Diseases, 2019, 68, 1650-1657.	2.9	42

#	Article	IF	Citations
19	Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. Journal of Clinical Gastroenterology, 2016, 50, 631-637.	1.1	40
20	In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infection Control and Hospital Epidemiology, 2015, 36, 1318-1323.	1.0	38
21	Activity of Cefiderocol and Comparators against Isolates from Cancer Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	38
22	Clinical Practice Patterns in Hospitalized Patients at Risk for Invasive Candidiasis. Annals of Pharmacotherapy, 2014, 48, 683-690.	0.9	36
23	Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient. Pediatric Infectious Disease Journal, 2016, 35, 1040-1042.	1.1	32
24	Regional variation in antibiotic prescribing among medicare part D enrollees, 2013. BMC Infectious Diseases, 2016, 16, 744.	1.3	31
25	Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. Diagnostic Microbiology and Infectious Disease, 2015, 81, 4-8.	0.8	29
26	IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort. Journal of Antimicrobial Chemotherapy, 2021, 76, 385-395.	1.3	29
27	Regional and seasonal variation in Clostridium difficile infections among hospitalized patients in the United States, 2001-2010. American Journal of Infection Control, 2015, 43, 435-440.	1.1	27
28	Clonal Emergence of Invasive Multidrug-Resistant Staphylococcus epidermidis Deconvoluted via a Combination of Whole-Genome Sequencing and Microbiome Analyses. Clinical Infectious Diseases, 2018, 67, 398-406.	2.9	27
29	Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure. Journal of Infection, 2017, 74, 243-247.	1.7	26
30	An Overview of the Treatment of Less Common Nonâ€“Lactoseâ€Fermenting Gramâ€Negative Bacteria. Pharmacotherapy, 2020, 40, 936-951.	1.2	26
31	Colonic Immunopathogenesis of Clostridium difficile Infections. Vaccine Journal, 2014, 21, 509-517.	3.2	25
32	Solithromycin: A novel ketolide antibiotic. American Journal of Health-System Pharmacy, 2017, 74, 875-887.	0.5	24
33	Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	23
34	Call for Antimicrobial Stewardship in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 2499.	2.6	22
35	Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infectious Diseases, 2019, 6, ofz416.	0.4	22
36	Healthcare Resource Utilization for Recurrent Clostridium difficile Infection in a Large University Hospital in Houston, Texas. PLoS ONE, 2014, 9, e102848.	1.1	21

#	Article	IF	Citations
37	Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. Journal of Antimicrobial Chemotherapy, 2018, 73, 2277-2283.	1.3	21
38	Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leukemia and Lymphoma, 2020, 61, 2488-2491.	0.6	21
39	Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy. Clinical Infectious Diseases, 2021, 72, 1507-1513.	2.9	19
40	New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides. Antimicrobial Agents and Chemotherapy, 2022, 66, e0261420.	1.4	19
41	Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiology and Infection, 2018, 146, 1101-1105.	1.0	18
42	Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	18
43	Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. Expert Review of Clinical Pharmacology, 2018, 11, 931-941.	1.3	17
44	Agricultural Applications for Antimicrobials. A Danger to Human Health: An Official Position Statement of the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2016, 36, 422-432.	1.2	15
45	Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 3585-3587.	1.3	13
46	Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Preâ€“ and Postâ€“Hurricane Harvey. Open Forum Infectious Diseases, 2019, 6, ofz138.	0.4	13
47	Significant publications on infectious diseases pharmacotherapy in 2015. American Journal of Health-System Pharmacy, 2017, 74, 238-252.	0.5	12
48	Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole. Antimicrobial Agents and Chemotherapy, 2015, 59, 6113-6116.	1.4	11
49	Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria. Current Infectious Disease Reports, 2016, 18, 39.	1.3	11
50	How common is subsequent central nervous system toxicity in asymptomatic patients with haematologic malignancy and supratherapeutic voriconazole serum levels?. Clinical Microbiology and Infection, 2017, 23, 387-390.	2.8	11
51	Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1637-1641.	2.0	11
52	Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. Journal of Antimicrobial Chemotherapy, 2016, 71, 727-730.	1.3	10
53	Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States. Open Forum Infectious Diseases, 2022, 9, ofac005.	0.4	10
54	Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various Minimum Inhibitory Concentrations. Journal of Pharmacy Practice, 2018, 31, 34-39.	0.5	9

#	Article	IF	Citations
55	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. International Journal of Antimicrobial Agents, 2019, 54, 346-350.	1.1	9
56	Clostridioides difficileInfection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clinical Infectious Diseases, 2021, 72, e460-e465.	2.9	9
57	Antimicrobial Stewardship in Cancer Patients: The Time is Now. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 772-775.	2.3	9
58	Significant publications on infectious diseases pharmacotherapy in 2014. American Journal of Health-System Pharmacy, 2015, 72, 1380-1392.	0.5	8
59	Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids. Mayo Clinic Proceedings, 2020, 95, 2038-2040.	1.4	8
60	Potential for Linezolid-Related Blindness: A Review of Spontaneous Adverse Event Reports. Pharmacotherapy, 2011, 31, 585-590.	1.2	7
61	Treatment of Extended-Spectrum Beta-Lactamase Enterobacteriaceae With Cefepime: The Dose Matters, Too. Clinical Infectious Diseases, 2013, 57, 915-916.	2.9	7
62	Echinocandin Use in Hospitalized Patients: A Multi-institutional Study. American Journal of the Medical Sciences, 2015, 349, 316-320.	0.4	7
63	RhOD immune globulin products for prevention of alloimmunization during pregnancy. American Journal of Health-System Pharmacy, 2015, 72, 267-276.	0.5	7
64	Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia. Open Forum Infectious Diseases, 2018, 5, ofy167.	0.4	7
65	Optimization of intravenous immune globulin use at a comprehensive cancer center. American Journal of Health-System Pharmacy, 2019, 76, S102-S106.	0.5	7
66	Extended Versus Short-Course Corticosteroid Taper Regimens in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Critically Ill Patients. Journal of Intensive Care Medicine, 2020, 35, 257-263.	1.3	7
67	Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC Î²-Lactamases?. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	5
68	Navigating manuscript assessment: The new practitionerâ€™s guide to primary literature peer review. Journal of Oncology Pharmacy Practice, 2019, 25, 94-100.	0.5	5
69	Outcomes of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant Enterococcus faecalis: Caution in Interpreting the Results. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
70	Does Switching Norepinephrine to Phenylephrine in Septic Shock Complicated by Atrial Fibrillation With Rapid Ventricular Response Improve Time to Rate Control?. Journal of Intensive Care Medicine, 2021, 36, 191-196.	1.3	5
71	Improving Antimicrobial Stewardship in Cancer Patients Through Implementation of Clinical Guidelines. Current Treatment Options in Infectious Diseases, 2017, 9, 333-346.	0.8	3
72	1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients. Open Forum Infectious Diseases, 2018, 5, S421-S422.	0.4	2

#	Article	IF	Citations
73	1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant. Open Forum Infectious Diseases, 2018, 5, S486-S486.	0.4	2
74	Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. Frontiers in Cellular and Infection Microbiology, 2022, 12, 848580.	1.8	2
75	Effectiveness and Safety of New Posaconazole Formulations in Patients With Hematologic Malignancy Receiving Antifungal Prophylaxis. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
76	Reply to Cheng and Chuang. Clinical Infectious Diseases, 2019, 69, 903-904.	2.9	1
77	Recommended Revisions to the National SEPâ€1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. Pharmacotherapy, 2020, 40, 368-371.	1.2	1
78	The role of tazobactamâ€based combinations for the management of infections due to extendedâ€spectrum Î²â€lactamaseâ€producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2021, 41, 864-880.	1.2	1
79	In vitro activity of imipenem/relebactam and comparator agents against clinical bacterial isolates from patients with cancer. Journal of Global Antimicrobial Resistance, 2022, 29, 1-6.	0.9	1
80	Effect of Colistin on Phospholipid-Based Activated Partial Thromboplastin Time Clotting Assay Results in Patients Receiving Concomitant Heparin Therapy. Pharmacotherapy, 2011, 31, 277-279.	1.2	0
81	Response to â€œEffect of geographic region and seasonality on Clostridium difficile incidence and hospital mortalityâ€. American Journal of Infection Control, 2015, 43, 1379.	1.1	0
82	Empiric Linezolid Treatment Is Associated With Adverse Short-Term Outcomes in Patients With Linezolid-Resistant Staphylococcus epidermidis Bloodstream Infections. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
83	How Common is Subsequent Central Nervous System (CNS) Toxicity in Patients With Hematologic Malignancy (HM) and Supratherapeutic Voriconazole (VRC) Serum Levels?. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
84	Previous Daptomycin Exposure Predicts Daptomycin Non-Susceptible Enterococcus faecium Bloodstream Infections in Adult Leukemia Patients. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
85	Evaluation of Fluoroquinolone Versus Other Antibiotic Prophylaxis Strategies in Adult Patients with AML Undergoing Induction Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S5-S6.	0.2	0
86	Ribotypes Matter, Significance of Clostridium difficile Ribotypes in Cancer Patients with Diarrhea. Open Forum Infectious Diseases, 2017, 4, S386-S387.	0.4	0
87	Risk Factors and Clinical Outcomes of Cancer Patients with Clostridium difficile Associated Diarrhea Co-infected with a Second Enteropathogen. Open Forum Infectious Diseases, 2017, 4, S362-S363.	0.4	0
88	Line of Service-Specific Performance and Antibiotic Prescribing Habits Following Introduction of a Two-Step Diagnostic Approach Using NAAT Followed by Enzyme Immunoassay in Cancer Patients with Suspected Clostridium difficile Infection. Open Forum Infectious Diseases, 2017, 4, S394-S394.	0.4	0
89	1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI). Open Forum Infectious Diseases, 2018, 5, S47-S47.	0.4	0
90	1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients. Open Forum Infectious Diseases, 2018, 5, S477-S477.	0.4	0

#	Article	IF	Citations
91	1055. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum Î²-Lactamase- Producing Enterobacteriaceae Bacteremia. Open Forum Infectious Diseases, 2018, 5, S315-S315.	0.4	0
92	Antibiotic Consideration in Transplant Recipients. , 2019, , 855-901.		0